This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.
Typical symptoms of angina (Canadian Cardiovascular Society [CCS] III-IV) and non-invasive evidence of myocardial ischemia; and
Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.
Occurred after the last coronary revascularization; and
Related to myocardial ischemia (location, extent, severity, et al).
Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).
Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
Active acute or chronic infection (human immunodeficiency virus [HIV], tuberculosis, et al).
Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).
Peking Union Medical College Hospital
Lead sponsor